Biomerica (BMRA) Competitors $3.40 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.42 +0.02 (+0.44%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. CLNN, SONN, ENLV, ALLK, GBIO, DYAI, OVID, DARE, NRSN, and MIRAShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Clene (CLNN), Sonnet BioTherapeutics (SONN), Enlivex Therapeutics (ENLV), Allakos (ALLK), Generation Bio (GBIO), Dyadic International (DYAI), Ovid Therapeutics (OVID), Dare Bioscience (DARE), NeuroSense Therapeutics (NRSN), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Clene Sonnet BioTherapeutics Enlivex Therapeutics Allakos Generation Bio Dyadic International Ovid Therapeutics Dare Bioscience NeuroSense Therapeutics MIRA Pharmaceuticals Biomerica (NASDAQ:BMRA) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability. Which has more volatility & risk, BMRA or CLNN? Biomerica has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Is BMRA or CLNN more profitable? Biomerica has a net margin of -85.42% compared to Clene's net margin of -8,306.00%. Clene's return on equity of 0.00% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-85.42% -85.90% -61.06% Clene -8,306.00%N/A -105.11% Do analysts prefer BMRA or CLNN? Clene has a consensus price target of $40.00, indicating a potential upside of 947.12%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media refer more to BMRA or CLNN? In the previous week, Clene had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for Clene and 0 mentions for Biomerica. Biomerica's average media sentiment score of 1.87 beat Clene's score of 0.93 indicating that Biomerica is being referred to more favorably in the media. Company Overall Sentiment Biomerica Very Positive Clene Positive Which has better valuation and earnings, BMRA or CLNN? Biomerica has higher revenue and earnings than Clene. Biomerica is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.68M1.52-$5.98M-$2.32-1.47Clene$340K92.92-$39.40M-$4.04-0.95 Do institutionals & insiders have more ownership in BMRA or CLNN? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 15.0% of Biomerica shares are owned by company insiders. Comparatively, 35.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryClene beats Biomerica on 11 of the 17 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.66M$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio-1.474.4521.0120.09Price / Sales1.52709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book1.095.008.125.65Net Income-$5.98M$30.99M$3.25B$257.91M7 Day Performance7.94%1.69%0.97%2.09%1 Month Performance3.66%9.20%7.36%11.13%1 Year Performance28.79%-1.25%31.31%18.40% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica1.3149 of 5 stars$3.40flatN/A+15.1%$8.66M$5.68M-1.4760Positive NewsCLNNClene3.4715 of 5 stars$3.73+3.9%$40.00+972.4%-18.6%$30.85M$340K-0.92100Analyst ForecastSONNSonnet BioTherapeutics3.787 of 5 stars$9.64+86.5%$20.00+107.5%+8.2%$30.56M$20K0.0010Gap DownHigh Trading VolumeENLVEnlivex Therapeutics2.7186 of 5 stars$1.28flat$10.00+681.3%-13.7%$30.27MN/A-1.9470Positive NewsALLKAllakos3.3852 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190GBIOGeneration Bio3.8544 of 5 stars$0.44+13.9%$7.33+1,566.7%-82.8%$29.50M$19.89M-0.41150News CoverageAnalyst ForecastStock SplitGap DownHigh Trading VolumeDYAIDyadic International3.0328 of 5 stars$0.97-1.9%$6.00+518.6%-31.5%$29.19M$3.34M-4.857Positive NewsGap DownOVIDOvid Therapeutics4.6769 of 5 stars$0.40-2.0%$3.13+687.4%-53.0%$28.22M$570K-1.1360Gap UpDAREDare Bioscience1.8546 of 5 stars$3.09+22.6%$12.00+288.3%-28.2%$27.35M$10K-18.1830High Trading VolumeNRSNNeuroSense Therapeutics2.5015 of 5 stars$2.00-3.4%$14.00+600.0%+150.1%$27.33MN/A-3.7010MIRAMIRA Pharmaceuticals2.5101 of 5 stars$1.54+20.3%$14.00+809.1%+146.3%$26.06MN/A-3.022Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Clene Alternatives Sonnet BioTherapeutics Alternatives Enlivex Therapeutics Alternatives Allakos Alternatives Generation Bio Alternatives Dyadic International Alternatives Ovid Therapeutics Alternatives Dare Bioscience Alternatives NeuroSense Therapeutics Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
